Historical Valuation
Profound Medical Corp (PROF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.08 is considered Undervalued compared with the five-year average of -8.12. The fair price of Profound Medical Corp (PROF) is between 37.57 to 57.09 according to relative valuation methord. Compared to the current price of 8.44 USD , Profound Medical Corp is Undervalued By 77.54%.
Relative Value
Fair Zone
37.57-57.09
Current Price：8.44
77.54%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Profound Medical Corp (PROF) has a current Price-to-Book (P/B) ratio of 7.20. Compared to its 3-year average P/B ratio of 4.93 , the current P/B ratio is approximately 45.86% higher. Relative to its 5-year average P/B ratio of 4.16, the current P/B ratio is about 73.06% higher. Profound Medical Corp (PROF) has a Forward Free Cash Flow (FCF) yield of approximately -16.18%. Compared to its 3-year average FCF yield of -13.20%, the current FCF yield is approximately 22.56% lower. Relative to its 5-year average FCF yield of -12.69% , the current FCF yield is about 27.46% lower.
P/B
Median3y
4.93
Median5y
4.16
FCF Yield
Median3y
-13.20
Median5y
-12.69
Competitors Valuation Multiple
AI Analysis for PROF
The average P/S ratio for PROF competitors is 112.99, providing a benchmark for relative valuation. Profound Medical Corp Corp (PROF.O) exhibits a P/S ratio of 7.08, which is -93.73% above the industry average. Given its robust revenue growth of 86.76%, this premium appears sustainable.
Performance Decomposition
AI Analysis for PROF
1Y
3Y
5Y
Market capitalization of PROF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PROF in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PROF currently overvalued or undervalued?
Profound Medical Corp (PROF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.08 is considered Undervalued compared with the five-year average of -8.12. The fair price of Profound Medical Corp (PROF) is between 37.57 to 57.09 according to relative valuation methord. Compared to the current price of 8.44 USD , Profound Medical Corp is Undervalued By 77.54% .
What is Profound Medical Corp (PROF) fair value?
PROF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Profound Medical Corp (PROF) is between 37.57 to 57.09 according to relative valuation methord.
How does PROF's valuation metrics compare to the industry average?
The average P/S ratio for PROF's competitors is 112.99, providing a benchmark for relative valuation. Profound Medical Corp Corp (PROF) exhibits a P/S ratio of 7.08, which is -93.73% above the industry average. Given its robust revenue growth of 86.76%, this premium appears sustainable.
What is the current P/B ratio for Profound Medical Corp (PROF) as of Jan 10 2026?
As of Jan 10 2026, Profound Medical Corp (PROF) has a P/B ratio of 7.20. This indicates that the market values PROF at 7.20 times its book value.
What is the current FCF Yield for Profound Medical Corp (PROF) as of Jan 10 2026?
As of Jan 10 2026, Profound Medical Corp (PROF) has a FCF Yield of -16.18%. This means that for every dollar of Profound Medical Corp’s market capitalization, the company generates -16.18 cents in free cash flow.
What is the current Forward P/E ratio for Profound Medical Corp (PROF) as of Jan 10 2026?
As of Jan 10 2026, Profound Medical Corp (PROF) has a Forward P/E ratio of -7.41. This means the market is willing to pay $-7.41 for every dollar of Profound Medical Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Profound Medical Corp (PROF) as of Jan 10 2026?
As of Jan 10 2026, Profound Medical Corp (PROF) has a Forward P/S ratio of 7.08. This means the market is valuing PROF at $7.08 for every dollar of expected revenue over the next 12 months.